Selank

Selank (TP-7)

A Russian-developed anxiolytic peptide with nootropic properties that reduces anxiety without sedation or dependence.

100% 50% · t½ Time → Serum level
Molecular Weight
751.87 Da
Half-Life
~1–2 minutes (intranasal)
Typical Dose
250–500 mcg
Cycle Length
2–4 weeks

Description

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as an analog of tuftsin (a natural immunomodulatory tetrapeptide). It has been approved in Russia and Ukraine for the treatment of generalized anxiety disorder and as a nootropic agent. Selank is notable for producing robust anxiolytic effects comparable to benzodiazepines in animal models, but without the sedation, cognitive impairment, tolerance development, or withdrawal syndrome associated with benzodiazepine use. This makes it particularly attractive for long-term anxiety management and cognitive enhancement. It has also demonstrated immunomodulatory properties, increasing the activity of natural killer (NK) cells and T-lymphocytes, and has been studied for antiviral effects.

Key Characteristics

Molecular FormulaC33H57N11O9
Molecular Weight751.87 Da
Half-Life~1–2 minutes (intranasal)
Administration RoutesIntranasal (preferred), Subcutaneous injection
Typical Dose250–500 mcg
Frequency2–3x daily

Investigated Benefits

  • Reduced anxiety without sedation
  • Improved cognitive function
  • Enhanced memory and learning
  • No tolerance or dependence
  • Immunomodulatory effects

* Benefits based on preclinical/animal research unless otherwise noted.